Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group

University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO 80045, USA.
Journal of Clinical Oncology (Impact Factor: 18.43). 03/2012; 30(14):1663-9. DOI: 10.1200/JCO.2011.37.8018
Source: PubMed


To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute lymphoblastic leukemia (ALL) enrolled onto Children's Oncology Group (COG) clinical trials between 1990 and 2005.
In total, 21,626 persons age 0 to 22 years were enrolled onto COG ALL clinical trials from 1990 to 2005, representing 55.8% of ALL cases estimated to occur among US persons younger than age 20 years during this period. This period was divided into three eras (1990-1994, 1995-1999, and 2000-2005) that included similar patient numbers to examine changes in 5- and 10-year survival over time and the relationship of those changes in survival to clinical covariates, with additional analyses of cause of death.
Five-year survival rates increased from 83.7% in 1990-1994 to 90.4% in 2000-2005 (P < .001). Survival improved significantly in all subgroups (except for infants age ≤ 1 year), including males and females; those age 1 to 9 years, 10+ years, or 15+ years; in whites, blacks, and other races; in Hispanics, non-Hispanics, and patients of unknown ethnicity; in those with B-cell or T-cell immunophenotype; and in those with National Cancer Institute (NCI) standard- or high-risk clinical features. Survival rates for infants changed little, but death following relapse/disease progression decreased and death related to toxicity increased.
This study documents ongoing survival improvements for children and adolescents with ALL. Thirty-six percent of deaths occurred among children with NCI standard-risk features emphasizing that efforts to further improve survival must be directed at both high-risk subsets and at those children predicted to have an excellent chance for cure.

Download full-text


Available from: Meenakshi Devidas, Mar 14, 2014
  • Source
    • "Pomimo znacznych postępów w onkologii i transplantologii komórkowej u dzieci, ciągle śmiertelność zależna od leczenia (TRM; treatment-related mortality) pozostaje zbyt wysoka. W najczęstszej chorobie nowotworowej, ostrej białaczce limfoblastycznej, TRM wynosi 2–4% [7] [8] [9]. Najczęstszą przyczyną zgonów są infekcje, a w grupie pacjentów standardowego ryzyka ALL zgony z powodu zakażenia są równie częste jak nawroty białaczki [10] [11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To analyze the incidence and outcome of infections with Staphylococcus spp. in children with malignancies treated in pediatric hematology and oncology (PHO) centers or undergoing hematopoietic stem cell transplantation (HSCT) over a period of 24 months.
    Pediatria polska 02/2015; 90(1):26-31. DOI:10.1016/j.pepo.2014.11.004
    • "Transplant-related mortality (TRM) has improved over the last 10–15 years, so that disease recurrence is now the main source of transplant failure (Moore et al, 2009; Gooley et al, 2010; Mateos et al, 2013). The key challenges to improving HSCT outcomes are to accurately identify HSCT patients at high risk of relapse and to establish more effective interventions (Verneris & Burke, 2010; Hunger et al, 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Minimal residual disease (MRD) during early chemotherapy is a powerful predictor of relapse in acute lymphoblastic leukaemia (ALL) and is used in children to determine eligibility for allogeneic haematopoietic stem cell transplantation (HSCT) in first (CR1) or later complete remission (CR2/CR3). Variables affecting HSCT outcome were analysed in 81 children from the ANZCHOG ALL8 trial. The major cause of treatment failure was relapse, with a cumulative incidence of relapse at 5 years (CIR) of 32% and treatment-related mortality of 8%. Leukaemia-free survival (LFS) and overall survival (OS) were similar for HSCT in CR1 (LFS 62%, OS 83%, n = 41) or CR2/CR3 (LFS 60%, OS 72%, n = 40). Patients achieving bone marrow MRD negativity pre-HSCT had better outcomes (LFS 83%, OS 92%) than those with persistent MRD pre-HSCT (LFS 41%, OS 64%, P < 0·0001) or post-HSCT (LFS 35%, OS 55%, P < 0·0001). Patients with B-other ALL had more relapses (CIR 50%, LFS 41%) than T-ALL and the main precursor-B subtypes including BCR-ABL1, KMT2A (MLL), ETV6-RUNX1 (TEL-AML1) and hyperdiploidy >50. A Cox multivariate regression model for LFS retained both B-other ALL subtype (hazard ratio 4·1, P = 0·0062) and MRD persistence post-HSCT (hazard ratio 3·9, P = 0·0070) as independent adverse prognostic variables. Persistent MRD could be used to direct post-HSCT therapy.
    British Journal of Haematology 10/2014; 168(3). DOI:10.1111/bjh.13142 · 4.71 Impact Factor
  • Source
    • "Some rare genetic syndromes exposed under radio therapy, and heavyweight born children are instances of some other factors which may improve the risk of ALL.The rate of survival in childhood ALL had a significant increase in some countries, during more than four decades (26). Five-year survival rates, since 1990 to 1994 raised to 83.7% (27). Some countries have achievedthe rate of long-term survival, in more than 80% of children suffering from ALL from 1 to 10 years old (28, 29). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Acute lymphoblastic leukemia (ALL) is one of the most prevalent hematologic malignancies in children. Although the cure rate of ALL has improved over the past decades, the most important reason for ALL treatment failure is multidrug resistance (MDR) phenomenon. The current study aims to explain the mechanisms involved in multidrug resistance of childhood ALL, and introduces ATP-binding cassette transporterA2 (ABCA2) as an ABC transporter gene which may have a high impact on MDR. Benefiting from articles published inreputable journals from1994 to date and experiments newly performed by our group, a comprehensive review is written about ABCA2 and its role in MDR regarding childhood ALL. ABCA2 transports drugs from the cytoplasm into the lysosomal compartment, where they may become degraded and exported from the cell. The aforementioned mechanism may contribute to MDR. It has been reported that ABCA2 may induce resistance to mitoxantrone, estrogen derivatives and estramustine. It is resistant to the aforementioned compounds. Furthermore, the overexpression ofABCA2 in methotrexate, vinblastine and/or doxorubicin treated Jurkat cells are observed in several publications. The recent study of our group showsthatthe overexpression ofABCA2 gene in children with ALL increases the risk of MDR by 15 times. ABCA2 is the second identified member of the ABCA; ABC transporters' subfamily. ABCA2 gene expression profile is suggested to be an unfavorable prognostic factor in ALL treatment. Better understanding of the MDR mechanisms and the factors involved may improve the therapeutic outcome of ALL by modifying the treatment protocols.
    07/2014; 4(3):118-26.
Show more